Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

BioNTech News

Ghko B 2026 Jan 29, 16:00

Top AI computing stocks to watch: NVIDIA (NVDA), AMD stock, Broadcom (AVGO)

Frances Wang 2026 Jan 29, 16:00

Big tech stock analysis: Meta stocks jumped 10%, what’s going on with Meta?

Frances Wang 2026 Jan 29, 16:00

Retail stocks to watch 2026: Costco (COST) stock, AMZN, Walmart (WMT)

Ghko B 2026 Jan 29, 16:00

Ripple (XRP) price prediction: XRP slides after recent surges, what’s next?

Frances Wang 2026 Jan 29, 16:00

Silver prices hit record highs: What’s driving Silver (XAG/USD) price?

Ghko B 2026 Jan 29, 16:00

Microsoft stock crashes more than 10%: Is MSFT stock a good buy now?

Frances Wang 2026 Jan 29, 16:00

Stock market analysis: S&P 500 slipped 9.02 points, MSFT stock dropped 10%

Ghko B 2026 Jan 28, 16:00

Gold price prediction 2026: Will gold (XAU) touch new highs in coming days?

Ghko B 2026 Jan 28, 16:00

Gold rally continues: What’s the best platform to trade gold (XAU/USD)?

Ghko B 2026 Jan 28, 16:00

Best AI infrastructure stocks to buy: NVDA stock, AVGO, Micron (MU)

Latest news

Show more
Noah Lee 2025 Dec 06, 17:50

ESMA Expansion Sparks Crypto, Fintech Slowdown Concerns in EU

Noah Lee 2025 Dec 06, 17:00

Bitcoin's 'Santa' Rally: Fed Rate Decision and 2026 Outlook

Liam James 2025 Dec 06, 12:40

Western Union Unveils Stable Card, Stablecoin Strategy to Combat Inflation

Ava Grace 2025 Dec 06, 11:50

Market Movers: Fed Rate Decision & Key Economic Data in Focus Next Week

Noah Lee 2025 Dec 06, 10:50

Central Bank Rate Decisions & Market Volatility Outlook: What to Expect

Emma Rose 2025 Dec 06, 09:40

Clear Street Prepares for IPO Amid Crypto Treasury Model Concerns

Ava Grace 2025 Dec 06, 09:30

Crypto Market Analysis and Regulatory Updates: December 6, 2024

Sophia Claire 2025 Dec 06, 08:00

Bitcoin Treasury Firms Face 'Darwinian Phase' Amid Market Shift

Info

Spread

0.8225

Spread (%)

0.7257 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Monday

14:31 - 20:59

Tuesday

14:31-20:59

Wednesday

14:31-20:59

Thursday

14:31-20:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

28543371264

Shares Outstanding

250930737

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-2.8

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Ghko B 2026 Jan 29, 16:00

CFD trading basics: Long position VS. short position, which is better?

Ghko B 2026 Jan 27, 16:00

What is a stochastic indicator: How to read the stochastic indicator?

Ghko B 2026 Jan 25, 16:00

CFD Trading Basics: Beginners Guide to Fundamental Analysis

Trustpilot